Seres Therapeutics (MCRB) AI Stock Analysis

• Market Cap: $143.48M
• Dividend Yield: N/A
• Average Volume (3M): 69.41K
• Price to Earnings (P/E): 25.4
• Beta (1Y): 1.49
• Revenue Growth: 448.44%
• EPS Growth: N/A
• Country: US
• Employees: 103
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.94
• Shares Outstanding: 9,046,519
• 10 Day Avg. Volume: 38,801
• 30 Day Avg. Volume: 69,407
• PEG Ratio: -189.72
• Price to Book (P/B): 187.37
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -17.34
• Enterprise Value/Market Cap: 1.44
• Enterprise Value/Revenue: 587.97
• Enterprise Value/Gross Profit: -11.73
• Enterprise Value/Ebitda: 21.34
• 1Y Price Target: $22.00
• Price Target Upside: 41.48% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): -8.97
• Revenue Forecast (FY): N/A

• Rating: 50 Neutral
• Price Target: $15.00 ▼(-3.54% Downside)

The score is held down primarily by weak financial performance (minimal revenue base, ongoing operating losses, and sizable cash burn) and a soft technical setup (below key moving averages with negative MACD). Offsetting this, the latest earnings call was constructive on clinical progress and near-term catalysts, but the investment case remains meaningfully funding-dependent, with a limited stated cash runway.

Positive Factors

SER-155 Breakthrough Therapy Designation

The FDA's breakthrough therapy designation for SER-155 highlights its potential to significantly impact the treatment of bloodstream infections, enhancing Seres' competitive position in the biotechnology sector.

Financial Improvements

The reduction in net loss and debt-free status improve Seres' financial health, providing more resources for R&D and operational stability, supporting long-term growth.

Strategic Partnership with Nestlé

The strategic partnership with Nestlé, reflected in board representation, strengthens Seres' market position and provides access to additional resources and expertise, supporting its growth strategy.

Negative Factors

Revenue Instability

The absence of stable revenue streams poses a risk to Seres' financial sustainability, limiting its ability to fund ongoing operations and R&D without external financing.

Leadership Transition

The departure of the CMO may disrupt clinical and regulatory strategies, affecting the continuity of leadership and potentially delaying critical development timelines.

Liquidity Challenges

Negative operating cash flows indicate ongoing liquidity issues, which could constrain Seres' ability to invest in growth opportunities and meet financial obligations.

Seres Therapeutics Business Overview & Revenue Model

Company Description

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

Seres Therapeutics generates revenue primarily through the development and commercialization of its microbiome therapeutic products. The company earns money by advancing its product candidates through clinical trials and ultimately bringing them to market. A significant portion of its revenue comes from collaborations and partnerships with larger pharmaceutical companies, which provide funding, research support, and milestone payments. Additionally, these partnerships often include royalty agreements based on the sales of successfully commercialized products. The company's financial performance is significantly influenced by the progress of its clinical trials, regulatory approvals, and the competitive landscape in the biotechnology sector.

Seres Therapeutics Financial Statement Overview

Summary

Seres Therapeutics faces significant financial challenges. The income statement reveals revenue instability and persistent profitability issues. The balance sheet highlights financial instability with high debt-to-equity ratios, and cash flow statements show ongoing liquidity challenges due to negative operating cash flows.

Income Statement

Seres Therapeutics has experienced significant revenue volatility over the years, with notable revenue in 2021 but zero revenue in 2024. The company has struggled with profitability, consistently reporting negative EBIT and EBITDA margins, though net income turned positive in 2024 due to non-operational gains. Overall, the income statement reveals challenges in achieving stable revenue and controlling operational costs.

Balance Sheet

The balance sheet shows a precarious financial position with fluctuating and often negative stockholders' equity, indicating potential solvency issues. The debt-to-equity ratio has been high, and the equity ratio is weak, highlighting reliance on debt financing. These aspects suggest financial instability and increased financial risk.

Cash Flow

Cash flow statements reveal persistent negative operating cash flows, indicating operational cash burn. Free cash flow has been consistently negative, reflecting cash outflows exceeding inflows from operations and investments. Despite occasional positive investing cash flows due to asset sales, the overall cash flow situation underscores liquidity challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	351.00K	0.00	0.00	0.00	144.93M	33.22M
Gross Profit	-17.59M	-3.53M	0.00	0.00	144.93M	-57.35M
EBITDA	9.67M	-120.30M	-181.42M	-170.93M	-56.72M	-77.31M
Net Income	5.39M	136.00K	-113.72M	-250.16M	-65.58M	-89.13M
Balance Sheet
Total Assets	143.47M	139.81M	358.60M	348.78M	354.86M	342.94M
Cash, Cash Equivalents and Short-Term Investments	47.64M	30.79M	127.97M	181.34M	290.71M	253.62M
Total Debt	85.25M	91.64M	198.78M	162.59M	49.21M	40.77M
Total Liabilities	99.78M	126.03M	403.46M	338.00M	223.35M	168.19M
Stockholders Equity	43.70M	13.78M	-44.86M	10.78M	131.51M	174.75M
Cash Flow
Free Cash Flow	-23.37M	-148.99M	-125.33M	-238.64M	-2.88M	-94.20M
Operating Cash Flow	-23.05M	-148.61M	-117.35M	-228.82M	6.69M	-93.61M
Investing Cash Flow	-313.00K	142.29M	10.58M	82.43M	64.09M	-158.89M
Financing Cash Flow	2.98M	-90.37M	71.70M	129.60M	1.18M	303.42M

Seres Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 15.55
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MCRB, the sentiment is Positive. The current price of 15.55 is above the 20-day moving average (MA) of 15.49, below the 50-day MA of 16.54, and above the 200-day MA of 14.16, indicating a neutral trend. The MACD of -0.47 indicates Negative momentum. The RSI at 46.89 is Neutral, neither overbought nor oversold. The STOCH value of 73.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MCRB.

Seres Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MCRB	50 Neutral	$143.48M	25.45	15.95%	―	448.44%	―
SRZN	50 Neutral	$171.17M	-0.87	―	―	-63.96%	-28.50%
ANIX	49 Neutral	$107.97M	-9.92	-57.94%	―	―	11.78%
CAMP	49 Neutral	$321.66M	-2.53	-172.70%	―	―	5.51%
CGTX	44 Neutral	$130.65M	-3.01	-109.73%	―	―	50.39%

Seres Therapeutics Corporate Events

Seres Therapeutics Reports Q3 Results and Business Updates

On November 5, 2025, Seres Therapeutics reported its third-quarter financial results and provided business updates, including progress on its SER-155 Phase 2 study for preventing bloodstream infections in stem cell transplant patients. The company is seeking funding to advance this study and anticipates interim results within 12 months of initiation. Additionally, Seres is exploring broader applications of SER-155 in immune-related conditions and has implemented cost-reduction measures to extend its operational funding through the second quarter of 2026.

The most recent analyst rating on (MCRB) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Seres Therapeutics stock, see the MCRB Stock Forecast page.